SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Anticipation of VK2735 subcutaneous maintenance-trial data is driving attention, with traders focused on whether weight loss is durable, dosing frequency can be reduced, and tolerability remains competitive with leading GLP-1 therapies. Bullish participants expect strong results to support a partnership or acquisition narrative, while skeptics emphasize the studys limited size, clinical uncertainty, dilution risk, and potential for a sell-the-news reaction.

Edison International is a renewable energy company, which operates through its subsidiaries. It supplies and distributes electric power, and also invests in energy services and technologies. The company was founded on July 4, 1886, and is headquartered in Rosemead, CA.

Edison International

California lawmakers wildfire legislation failed to provide the liability protections investors expected, leaving Edison International exposed to potentially significant wildfire claims and prompting analyst downgrades. Traders are divided between viewing the selloff as an overreaction and warning that unresolved liability, credit risk, and possible dividend pressure could prolong the weakness.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Anticipation of Teslas invite-only Cybercab launch and reported additions to its Texas robotaxi fleet are driving the move, with traders also watching FSD and autonomy updates. Bulls expect a broader robotaxi rollout and short squeeze, while skeptics question the technology, valuation, and whether the event will become a sell-the-news catalyst.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

New real-world payment and settlement partnerships are driving attention, including Amalfi Jets planned acceptance of cryptocurrency through a Keeta wallet and the broader Visa Direct and ASK Group initiatives. Traders view these developments as validation of Keetas financial-rails strategy, while skeptics remain concerned about execution, limited network usage, and the lingering effects of the security breach.

Corvex, Inc. is an AI cloud computing company, which specializes in GPU-accelerated infrastructure for AI workloads. Its products include GPU Clusters, Confidential Computing, Inference as a Service and GPU Node. The firm offers solutions include AI model builders, enterprises, federal and sovereign solutions. The company was founded by Seth Mitchell Demsey, Jay Crystal on October 21, 2024 and is headquartered in Arlington, VA.

Corvex Inc.

Movano Inc

Corvexs announced expansion of its AI data-center capacity and multi-year agreement to provide NVIDIA Blackwell GPU clusters to an AI customer is driving attention, as traders view the deal as a major shift from Movanos wearable-health business toward AI infrastructure. The community is largely bullish on momentum and a potential short squeeze, while skeptics cite the discounted private placement, dilution risk, and execution uncertainty.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Alleged Grand Theft Auto VI gameplay and build leaks are driving the selloff, with traders debating whether they signal unfinished gameplay, performance issues, a delay, or limited damage because the footage may be outdated and could amplify publicity. Bullish participants view the weakness as a buying opportunity ahead of the launch and Netflix preview, while skeptics argue expectations and GTA VI monetization are already priced in.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoins breakout and broader crypto-market rally are driving attention to Coinbase as a high-beta proxy for crypto prices, trading activity, and potential short covering. Traders are broadly bullish on further upside, though others argue COIN is lagging Bitcoin and remains vulnerable to sharp pullbacks, rate concerns, and profit-taking.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hawkish Federal Reserve messaging at Jackson Hole, rising Treasury yields, and increased expectations for a rate hike are pressuring small caps and driving bearish positioning in IWM. Traders are focused on heavy put activity and failed support levels, while some bulls argue that technical support could spark a rebound, leaving the conversation centered on downside risk versus a relief bounce.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

Treasury Secretary Scott Bessents expanded long-term bond buyback plans, potentially supported by the Treasurys cash account, have put TLT in focus as traders debate whether official intervention can push long-term yields lower. Bulls anticipate a short squeeze and near-term TLT strength, while bears argue persistent inflation, fiscal deficits and hawkish Fed policy will keep yields elevated and limit the buybacks effect.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Bitcoins rally, combined with Strives continued purchases that expanded its Bitcoin treasury, has driven attention to ASST as a high-beta Bitcoin proxy. Traders are broadly bullish and frequently discuss short-squeeze potential, while others caution that dilution, overbought conditions, and the stocks speculative structure could limit gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

Key PointsAdded 296,944 shares of Trevi Therapeutics; estimated buy value ~$3.32 million based on quarterly average price...

HC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

HC Wainwright reaffirmed a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday...

Trevi Therapeutics Q1 Earnings Call Highlights

Trevi Therapeutics (NASDAQ:TRVI) management used the company's first-quarter 2026 earnings call to outline upcoming clinical milestones for its chronic cough programs and to highlight an expanded cash runway following an April equity offering.

Clinical program updates and upcoming trial starts
Pres...

Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07...

Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Thursday

Trevi Therapeutics (NASDAQ:TRVI) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...

Peregrine Capital Management LLC Lowers Stake in Trevi Therapeutics, Inc. $TRVI

Peregrine Capital Management LLC lowered its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 18.2% during the 4th quarter, according to its most recent disclosure with...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given a consensus recommendation of "Buy" by the twelve ratings firms that are currently covering the firm, Marketbeat.com reports...

TRVI Stock’s Five-Day Rally Pushes It To An All-Time High – Here’s What’s Happening

Equity

The biotech firm priced its $150 million underwritten public offering at $13 per share, representing a roughly 10% discount from Thursday’s closing price.

Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Still a Buy?

Trevi Therapeutics (NASDAQ:TRVI) Sees Large Volume Increase - Here's Why...

D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)

D. Boral Capital reaffirmed a "buy" rating and set a $19.00 price target on shares of Trevi Therapeutics in a report on Friday...

Reported GAAP EPS of -$0.11 down -22.22% YoY

Trevi Therapeutics remains unprofitable with a growing accumulated deficit and faces intense competition from better-resourced pharmaceutical companies that could render the company's product development efforts obsolete or commercially noncompetitive.

Trevi Therapeutics is advancing its clinical pipeline with the initiation of Phase 3 trials for Haduvio and maintains a strong cash position to support development programs through at least 2030.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Trevi Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

TRVI Trevi Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest TRVI News